StockWatch
·

Windlas Biotech Ltd Q2 FY27 Results

WINDLASQ2 FY27 Results
Filing
Result:Steady· Market: Surged#Margin squeeze
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue263.916.4%18.7%
Total Income267.775.8%18.5%
Expenditure244.476.2%20.8%
PBT23.301.6%1.2%
Net Profit18.052.3%1.4%
OPM11.13%0.38pp1.71pp
NPM6.74%0.23pp1.13pp
EPS8.753.4%3.2%
View full financials

Revenue grew a healthy 18.7% YoY but EBITDA margin compressed ~170bps to 11.1%, leaving adjusted PAT growth at just 1.4% — core-metric growth not translating to the bottom line caps this at in-line/steady.

Q2 FY-2027 RESULTS · WINDLAS

Windlas Biotech: revenue +18.7% YoY, margin squeeze caps PAT growth at 1.4%

PAT +1.42% YoY · revenue +18.67% · margins compressing

05 Nov 2026 · 3 min read
Revenue

₹263.91 Cr

+18.67% YoY

PAT (standalone)

₹18.05 Cr

+1.42% YoY

Net margin

6.74%

-1.1pp YoY

EPS

₹8.75

Windlas Biotech's standalone revenue grew 18.7% YoY to ₹263.9 Cr in Q2 FY27 (quarter ended 30-Sep-2026), extending its growth run from ₹222.4 Cr a year ago, and rose 6.4% sequentially from ₹248.1 Cr in Q1 FY27. Profit after tax grew just 1.4% YoY to ₹18.05 Cr (₹17.80 Cr a year ago) and 2.3% QoQ (₹17.65 Cr) — profit growth trailing revenue growth by a wide margin, which is the core story of the quarter. Neither period carries exceptional items, so the gap is a genuine margin effect rather than a base-effect distortion. No Q2 FY27-specific street estimates for Windlas turned up in a search, so the print cannot be graded against consensus this quarter (vsStreet: unknown).

The scoreboard

Q2 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹263.91 Cr+6.4%+18.7%
Expenses₹244.47 Cr+6.2%+20.8%
PAT₹18.05 Cr+2.26%+1.42%
Net margin6.74%-0.2pp-1.1pp
EPS₹8.75+3.4%+3.2%

Operating margin (EBITDA/revenue) came in near 11.1%, down from 12.8% a year ago though up slightly from 10.75% in Q1 FY27; net margin was 6.8%, down from 7.9% YoY and roughly flat sequentially (7.0%) — margin compression is a YoY phenomenon, not a QoQ one. Basic EPS of ₹8.75 rose 3.2% YoY and 3.4% QoQ, outpacing PAT growth, because the share count fell roughly 2.2% after the company completed a ₹47 Cr tender-offer buyback of 470,000 shares this half, on top of a ₹130 Cr FY26 dividend payout; both calls on cash were funded partly by a ₹16.4 Cr rise in short-term borrowings (₹29.9 Cr to ₹46.2 Cr).

₹
801.84899.52997.21,094.881,192.5692208-0308-2509-1710-1211-0411-05Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹922, down 11% over the past month of trading.

₹ Cr
06.7413.4820.2217.66Q1 FY26rev ₹210 Cr17.8Q2 FY26rev ₹222 Cr15Q3 FY26rev ₹233 Cr15.99Q4 FY26rev ₹238 Cr17.65Q1 FY27rev ₹248 Cr18.05Q2 FY27rev ₹264 Cr
Quarterly standalone PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.

What management guided (1 FY-2027 call)
Plant 6 commercialization end of H1 FY27. Capacity potential: ₹1,100 Cr via Plant 6, expandable ₹100–150 Cr via debottlenecking. No FY27 full-year revenue target disclosed; management focuses on disciplined execution over aggressive growth targets.

— This quarter: met

Management had guided on the Q1 FY27 call that Plant 6 would commercialize by the end of H1 FY27 — i.e., by this quarter-end — adding capacity toward ₹1,100 Cr of revenue. This filing does not name Plant 6 directly, but the balance sheet is consistent with that timeline: capital work-in-progress fell to nil from ₹56.2 Cr as of March 2026, while property, plant & equipment rose ₹29 Cr and right-of-use assets rose ₹35 Cr — a capitalization pattern that lines up with a facility going live in the exact window management flagged. No management press release accompanied this filing, so there is no fresh management commentary to check the numbers against this quarter. Separately, the same board meeting approved a leadership transition — Ashok Kumar Windlass stepped down as Whole-time Director as part of long-term succession planning, continuing as Senior Management Personnel/Founder President, while Hitesh Windlass was appointed Chairman — and the company had disclosed a cybersecurity incident on 30-Oct-2026, five days before results, with no financial impact quantified anywhere in this statement.

  • W1

    OPM trajectory: slipped YoY to ~11.1% from 12.8% — watch whether Plant 6's capitalization (this half) lifts operating leverage from Q3 FY27, per management's ₹1,100 Cr capacity guidance

  • W2

    Working capital: trade receivables up ₹60.9 Cr and trade payables up ₹67.3 Cr in H1 FY27, partly funded by a ₹16.4 Cr rise in short-term borrowings — watch if growth keeps absorbing cash

  • W3

    EPS quality: share count down ~2.2% post-buyback is currently doing more work than PAT growth (+1.4% YoY) — confirm EPS growth isn't solely buyback-driven once PAT growth normalizes

Standalone only — company stopped preparing consolidated statements from 1-Apr-2026 after dissolving its sole, non-operating US subsidiary (Windlas Inc.); source figures in ₹ Million, converted to ₹ Cr (÷10); no exceptional items either period so no YoY adjustment needed; our year-ago comparator was tagged 'consolidated' but the dissolved subsidiary was non-operating, so divergence from standalone is expected to be negligible.

Informational and educational content only. Not investment advice.